<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17475" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Amoxicillin Clavulanate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Evans</surname>
            <given-names>Justin</given-names>
          </name>
          <aff>Desert Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hanoodi</surname>
            <given-names>Maryam</given-names>
          </name>
          <aff>Vassar Brothers Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wittler</surname>
            <given-names>Micah</given-names>
          </name>
          <aff>Western University of Health Sciences</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Justin Evans declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maryam Hanoodi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Micah Wittler declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17475.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Amoxicillin-clavulanate is an antibiotic commonly used in emergency departments and primary care offices worldwide. This drug combination&#x000a0;offers broader coverage by combining amoxicillin, a penicillin derivative effective against gram-positive and gram-negative bacteria, with clavulanic acid, which counteracts &#x003b2;-lactamase&#x02013;producing strains. This medication&#x000a0;is effective against methicillin-sensitive <italic toggle="yes">Staphylococcus aureus</italic> (MSSA) and <italic toggle="yes">Neisseria</italic> species. Indications for amoxicillin-clavulanate administration also include community-acquired pneumonia (CAP), chronic group A streptococci carriers, and small intestinal bacterial overgrowth (SIBO); the&#x000a0;efficacy of amoxicillin-clavulanate in treating SIBO approximates 50%.&#x000a0;Amoxicillin-clavulanate is also&#x000a0;indicated for treating&#x000a0;acute bacterial rhinosinusitis; the Infectious Diseases Society of America (IDSA) and the American Academy of Otolaryngology's Head and Neck Surgery guidelines recommend this combination medication over amoxicillin alone.</p>
        <p>Healthcare professionals play a critical role in antimicrobial stewardship by prescribing amoxicillin-clavulanate appropriately to prevent resistance. Understanding&#x000a0;this drug's&#x000a0;indications, contraindications, and associated adverse&#x000a0;reactions&#x000a0;aids in optimizing dosage regimens. Monitoring for interactions and understanding clinical toxicology is essential for safe and effective patient care. Familiarity with the pharmacological features of amoxicillin-clavulanate enables informed decision-making, contributing to improved patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess the antimicrobial coverage of amoxicillin-clavulanate based on its mechanism of action.</p></list-item><list-item><p>Identify the indications for amoxicillin-clavulanate administration.</p></list-item><list-item><p>Identify&#x000a0;the adverse&#x000a0;reactions&#x000a0;associated with amoxicillin-clavulanate administration.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to optimize amoxicillin-clavulanate administration, improve patient outcomes, and prevent antimicrobial resistance.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17475&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17475">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17475.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Amoxicillin-clavulanate is one of the most frequently&#x000a0;prescribed antimicrobial combinations in emergency departments and primary care offices worldwide. Amoxicillin is a penicillin derivative and has similar activity against gram-positive and gram-negative bacteria, including&#x000a0;<italic toggle="yes">Listeria monocytogenes</italic>,&#x000a0;<italic toggle="yes">Haemophilus influenzae</italic>, <italic toggle="yes">Moraxella catarrhalis,&#x000a0;</italic><italic toggle="yes">Corynebacterium diphtheria</italic>, <italic toggle="yes">Escherichia coli</italic>, and&#x000a0;<italic toggle="yes">Klebsiella pneumoniae</italic>, in addition to various&#x000a0;<italic toggle="yes">Streptococcus</italic>,&#x000a0;<italic toggle="yes">Enterococcus</italic>,&#x000a0;<italic toggle="yes">Salmonella</italic>, <italic toggle="yes">Shigella</italic>, and <italic toggle="yes">Borrelia&#x000a0;</italic>species. With the addition of clavulanic acid, the&#x000a0;coverage extends to all &#x003b2;-lactamase-producing strains of these organisms and methicillin-sensitive <italic toggle="yes">Staphylococcus</italic>
<italic toggle="yes">aureus</italic> (MSSA), <italic toggle="yes">Neisseria</italic> species,&#x000a0;<italic toggle="yes">Proteus</italic> species, <italic toggle="yes">Pasteurella multocida</italic>, and <italic toggle="yes">Capnocytophaga canimorsus,</italic> among others.<xref ref-type="bibr" rid="article-17475.r1">[1]</xref><xref ref-type="bibr" rid="article-17475.r2">[2]</xref>&#x000a0;</p>
        <p>The American Thoracic Society and Infectious Diseases Society of America guidelines provide initial treatment strategies for patients with community-acquired pneumonia. For patients with comorbidities, these guidelines recommend combination therapy involving amoxicillin-clavulanate or cephalosporin combined with a macrolide or doxycycline. Alternatively, monotherapy with a respiratory fluoroquinolone is also considered appropriate.<xref ref-type="bibr" rid="article-17475.r3">[3]</xref>&#x000a0;The American College of Gastroenterology guidelines suggest using amoxicillin-clavulanate&#x000a0;to treat small intestinal bacterial overgrowth (SIBO). However,&#x000a0;its efficacy is&#x000a0;only about 50% for this indication.<xref ref-type="bibr" rid="article-17475.r4">[4]</xref>&#x000a0;According to the Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for Acute Bacterial Rhinosinusitis (ABRS), amoxicillin-clavulanate is preferred over amoxicillin alone as the initial antibiotic therapy.<xref ref-type="bibr" rid="article-17475.r5">[5]</xref>&#x000a0;The American Academy of Otolaryngology's Head and Neck Surgery&#x000a0;guidelines also endorse amoxicillin-clavulanate for treating ABRS.<xref ref-type="bibr" rid="article-17475.r6">[6]</xref>&#x000a0;The IDSA recommends using amoxicillin-clavulanate in specific scenarios for chronic group A <italic toggle="yes">Streptococcus</italic> (GAS) carriers. These indications include a community outbreak of acute rheumatic fever, acute post-streptococcal glomerulonephritis, or invasive group A streptococcal (GAS) infection; an outbreak of GAS pharyngitis within a closed or partially closed community;&#x000a0;for individuals with a family or personal history of acute rheumatic fever; or when tonsillectomy is considered for patients who are <italic toggle="yes">Streptococcus</italic> carriers.<xref ref-type="bibr" rid="article-17475.r7">[7]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Amoxicillin-clavulanate is approved by the United States&#x000a0;Food and Drug Administration&#x000a0;to treat the conditions listed below.<xref ref-type="bibr" rid="article-17475.r8">[8]</xref><xref ref-type="bibr" rid="article-17475.r3">[3]</xref><xref ref-type="bibr" rid="article-17475.r9">[9]</xref><xref ref-type="bibr" rid="article-17475.r10">[10]</xref><xref ref-type="bibr" rid="article-17475.r6">[6]</xref><xref ref-type="bibr" rid="article-17475.r11">[11]</xref><xref ref-type="bibr" rid="article-17475.r12">[12]</xref><xref ref-type="bibr" rid="article-17475.r13">[13]</xref><xref ref-type="bibr" rid="article-17475.r14">[14]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Aspiration pneumonia</p>
          </list-item>
          <list-item>
            <p>Community-acquired pneumonia</p>
          </list-item>
          <list-item>
            <p>Acute bacterial rhinosinusitis</p>
          </list-item>
          <list-item>
            <p>Urinary tract infection</p>
          </list-item>
          <list-item>
            <p>Acute otitis media</p>
          </list-item>
          <list-item>
            <p>Skin&#x000a0;or soft tissue infection</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Amoxicillin-clavulanate may help manage the conditions listed below.<xref ref-type="bibr" rid="article-17475.r15">[15]</xref><xref ref-type="bibr" rid="article-17475.r7">[7]</xref><xref ref-type="bibr" rid="article-17475.r16">[16]</xref><xref ref-type="bibr" rid="article-17475.r17">[17]</xref><xref ref-type="bibr" rid="article-17475.r18">[18]</xref><xref ref-type="bibr" rid="article-17475.r19">[19]</xref><xref ref-type="bibr" rid="article-17475.r20">[20]</xref><xref ref-type="bibr" rid="article-17475.r21">[21]</xref><xref ref-type="bibr" rid="article-17475.r22">[22]</xref><xref ref-type="bibr" rid="article-17475.r23">[23]</xref><xref ref-type="bibr" rid="article-17475.r24">[24]</xref><xref ref-type="bibr" rid="article-17475.r25">[25]</xref>&#x000a0;These indications have not been approved by the FDA.</p>
        <list list-type="bullet">
          <list-item>
            <p>Bite wounds</p>
          </list-item>
          <list-item>
            <p>Group A streptococcal infections</p>
          </list-item>
          <list-item>
            <p>Impetigo</p>
          </list-item>
          <list-item>
            <p>Acute exacerbations of chronic obstructive pulmonary disease and bronchiectasis</p>
          </list-item>
          <list-item>
            <p>Diabetic foot infections</p>
          </list-item>
          <list-item>
            <p>Odontogenic infections</p>
          </list-item>
          <list-item>
            <p>Peritonsillar cellulitis or abscess</p>
          </list-item>
          <list-item>
            <p>Thoracic empyema (<italic toggle="yes">Actinomyces naeslundii</italic>)</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Pasteurella multocida</italic>&#x000a0;bacteremia</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Bacillus anthracis</italic>&#x000a0;(anthrax) postexposure prophylaxis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17475.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Amoxicillin is a broad-spectrum &#x003b2;-lactam penicillin derivative that targets and kills bacteria by inhibiting the biosynthesis of the peptidoglycan layer of the bacterial cell wall. This outermost&#x000a0;layer of the cell wall is responsible for the structural integrity of the cell. Peptidoglycan synthesis involves the facilitation of DD-transpeptidases, a type of penicillin-binding protein (PBP). Amoxicillin works by binding to these PBPs and inhibiting peptidoglycan synthesis, which interrupts the construction of the cell wall and ultimately leads to the destruction, or lysis, of the bacteria.<xref ref-type="bibr" rid="article-17475.r1">[1]</xref><xref ref-type="bibr" rid="article-17475.r26">[26]</xref></p>
        <p>Various bacterial species have progressively developed resistance&#x000a0;to standard &#x003b2;-lactam antimicrobials&#x000a0;by producing enzymes called &#x003b2;-lactamases. These enzymes target and hydrolyze the &#x003b2;-lactam ring,&#x000a0;a key component of&#x000a0;penicillin and similar antimicrobials. Clavulanic acid is a &#x003b2;-lactamase inhibitor often combined with amoxicillin to&#x000a0;extend its coverage and&#x000a0;reduce resistance.&#x000a0;Clavulanate has&#x000a0;minimal antimicrobial activity&#x000a0;but&#x000a0;prevents bacterial&#x000a0;degradation of &#x003b2;-lactams by binding and deactivating &#x003b2;-lactamases, ensuring amoxicillin's antimicrobial&#x000a0;mechanism remains intact.<xref ref-type="bibr" rid="article-17475.r1">[1]</xref><xref ref-type="bibr" rid="article-17475.r26">[26]</xref><xref ref-type="bibr" rid="article-17475.r27">[27]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;No significant difference has been observed between patients taking amoxicillin after fasting or with meals. However, clavulanate potassium&#x000a0;absorption is increased&#x000a0;when taken with food.</p>
        <p><bold>Distribution:&#x000a0;</bold>Amoxicillin is approximately 18% bound to serum proteins, and clavulanic acid is about 25% bound.&#x000a0;Additionally, amoxicillin is transported by organic anion transporters (OATs) 1 and 3. Amoxicillin diffuses readily into most body tissues and fluids, except the brain and spinal fluid. Amoxicillin and clavulanic acid&#x000a0;have been detected&#x000a0;in middle ear effusions.</p>
        <p><bold>Metabolism: </bold>Amoxicillin is primarily eliminated unchanged in the urine. Between 50% and 85% of the oral dose is&#x000a0;eliminated within 6 hours.&#x000a0;The&#x000a0;metabolism of amoxicillin involves various processes, including oxidation, hydroxylation, and deamination. In contrast, clavulanate&#x000a0;is metabolized considerably, and between 25% and 40% of the drug is excreted unchanged in the urine.<xref ref-type="bibr" rid="article-17475.r28">[28]</xref><xref ref-type="bibr" rid="article-17475.r29">[29]</xref><xref ref-type="bibr" rid="article-17475.r30">[30]</xref></p>
        <p><bold>Elimination:&#x000a0;</bold>After oral administration of amoxicillin and clavulanate potassium, the approximate half-life is 1.3 hours for amoxicillin and 1 hour for clavulanic acid.</p>
      </sec>
      <sec id="article-17475.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Amoxicillin-clavulanate is only available in oral formulations and, like most bactericidal antibiotics, needs to be administered at regularly scheduled intervals to minimize differences in the peak and trough concentrations. This approach maintains consistent serum concentrations&#x000a0;above the minimum inhibitory concentration (MIC) needed to destroy the targeted organism, generally accomplished with administration every 8 to 12 hours.<xref ref-type="bibr" rid="article-17475.r31">[31]</xref>&#x000a0;Amoxicillin-clavulanate is available as immediate or extended-release tablets, chewable tablets, and reconstituted suspensions. Taking this antimicrobial with food is recommended to enhance absorption and minimize any adverse gastrointestinal symptoms.<xref ref-type="bibr" rid="article-17475.r10">[10]</xref><xref ref-type="bibr" rid="article-17475.r26">[26]</xref></p>
        <p>The oral suspension is available&#x000a0;for reconstitution in the following combinations. For better palatability in the pediatric population, apple, banana cream, bubble gum, cherry, or watermelon flavoring may be supplemented. Before interchanging strengths, dosage forms should be verified to contain the same amoxicillin-to-clavulanic acid ratio. The amoxicillin 600 mg and potassium clavulanate 42.9 mg combination is not interchangeable with other immediate-release formulations. To maximize its longevity and effectiveness, the reconstituted solution should be refrigerated and shaken well before administration.</p>
        <list list-type="bullet">
          <list-item>
            <p>Amoxicillin 125 mg and potassium clavulanate 31.25 mg per 5 mL</p>
          </list-item>
          <list-item>
            <p>Amoxicillin 200 mg and potassium clavulanate 28.5 mg per 5 mL</p>
          </list-item>
          <list-item>
            <p>Amoxicillin 250 mg and potassium clavulanate 62.5 mg per 5 mL</p>
          </list-item>
          <list-item>
            <p>Amoxicillin 400 mg and potassium clavulanate 57 mg per 5 mL</p>
          </list-item>
          <list-item>
            <p>Amoxicillin 600 mg and potassium clavulanate 42.9 mg per 5 mL</p>
          </list-item>
        </list>
        <p>Oral tablets are available in the following combinations.&#x000a0;Before interchanging strengths, dosage forms should be verified to contain the same amoxicillin-to-clavulanic acid ratio.&#x000a0;The combination of amoxicillin&#x000a0;1000 mg and potassium clavulanate&#x000a0;62.5 mg is not interchangeable with other immediate-release formulations. Amoxicillin 250 mg and potassium clavulanate 125 mg tablets are not recommended for pediatric patients&#x000a0;due to the higher amount of clavulanate than other strengths.</p>
        <list list-type="bullet">
          <list-item>
            <p>Amoxicillin 250 mg and potassium clavulanate 125 mg</p>
          </list-item>
          <list-item>
            <p>Amoxicillin 500 mg and&#x000a0;potassium clavulanate 125 mg</p>
          </list-item>
          <list-item>
            <p>Amoxicillin 875 mg and potassium clavulanate 125 mg</p>
          </list-item>
          <list-item>
            <p>Amoxicillin 200 mg and potassium clavulanate 28.5 mg (chewable)</p>
          </list-item>
          <list-item>
            <p>Amoxicillin 400 mg and potassium clavulanate 57 mg (chewable)</p>
          </list-item>
          <list-item>
            <p>Amoxicillin 1000 mg and potassium clavulanate 62.5 mg (12-hour,&#x000a0;extended-release)</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Immediate-release:</bold> 500 mg every 8 to 12 hours, or&#x000a0;875 mg every 12 hours</p>
          </list-item>
          <list-item>
            <p><bold>Extended-release:</bold> 2 g every 12 hours</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric Dosage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Weight over 40 kg:</bold>&#x000a0;250 or 500 mg every 8 hours, or 500 or 875 mg every 12 hours</p>
          </list-item>
          <list-item>
            <p><bold>12 weeks and older:</bold>&#x000a0;Amoxicillin 20 to 40 mg/kg/day divided every 8 hours, or 25 to 45 mg/kg/day&#x000a0;divided every 12 hours</p>
          </list-item>
          <list-item>
            <p><bold>Neonates and infants:</bold>&#x000a0;Amoxicillin 30 mg/kg/day divided every 12 hours. The 125 mg per 5 mL oral suspension is recommended for these patients.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;This&#x000a0;medication should be discontinued if signs or symptoms of hepatitis (eg, hepatic dysfunction, cholestatic jaundice) occur.&#x000a0;Clinicians should monitor liver function in patients with hepatic impairment. The product label has no information&#x000a0;regarding this patient population.<xref ref-type="bibr" rid="article-17475.r32">[32]</xref></p>
        <p><bold>Renal impairment:&#x000a0;</bold>As the kidney primarily eliminates amoxicillin from the body, dosage adjustment is recommended for patients with severe renal impairment (CrCL&#x0003c;30 mL/min).<xref ref-type="bibr" rid="article-17475.r33">[33]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Amoxicillin-clavulanate&#x000a0;is a Pregnancy Category B medication.</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Amoxicillin is excreted in human milk and may lead to sensitization of nursing infants. Restlessness, diarrhea,&#x000a0;or rash&#x000a0;may occur occasionally. Amoxicillin-potassium clavulanate should be administered cautiously to a patient who is breastfeeding.<xref ref-type="bibr" rid="article-17475.r34">[34]</xref></p>
        <p><bold>Pediatric patients: </bold>See above.</p>
        <p><bold>Older patients:</bold> The dosage&#x000a0;of amoxicillin-clavulanate for older&#x000a0;adults should be based on renal function and any concomitant&#x000a0;medications.<xref ref-type="bibr" rid="article-17475.r35">[35]</xref></p>
      </sec>
      <sec id="article-17475.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Amoxicillin-clavulanate is&#x000a0;generally safe and well-tolerated in the general population, with the vast majority of adverse effects being mild gastrointestinal symptoms, including:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Vomiting</p>
          </list-item>
          <list-item>
            <p>Abdominal discomfort</p>
          </list-item>
        </list>
        <p>The incidence of diarrhea is higher in patients receiving amoxicillin-clavulanate&#x000a0;than&#x000a0;with amoxicillin alone.<xref ref-type="bibr" rid="article-17475.r36">[36]</xref> Additionally, there is a moderately increased risk of secondary <italic toggle="yes">Clostridioides difficile</italic> colitis compared&#x000a0;to other antimicrobial classes.&#x000a0;Women taking this medication can also develop vaginitis secondary to vaginal mycosis or candidiasis.<xref ref-type="bibr" rid="article-17475.r37">[37]</xref></p>
        <p>Dermatologic effects are less common and generally&#x000a0;associated with&#x000a0;hypersensitivity reactions. These reactions range from simple pruritis or urticaria to severe and life-threatening manifestations, such as anaphylaxis, Steven-Johnson syndrome, or toxic epidermal necrolysis. Classically, a morbilliform rash will present shortly after initiation of amoxicillin in patients misdiagnosed&#x000a0;with streptococcal pharyngitis when they actually have infectious mononucleosis.<xref ref-type="bibr" rid="article-17475.r26">[26]</xref><xref ref-type="bibr" rid="article-17475.r38">[38]</xref><xref ref-type="bibr" rid="article-17475.r39">[39]</xref><xref ref-type="bibr" rid="article-17475.r40">[40]</xref></p>
        <p>Rare complications of amoxicillin-clavulanate&#x000a0;administration&#x000a0;include:<xref ref-type="bibr" rid="article-17475.r41">[41]</xref><xref ref-type="bibr" rid="article-17475.r42">[42]</xref><xref ref-type="bibr" rid="article-17475.r43">[43]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Prolonged prothrombin time</p>
          </list-item>
          <list-item>
            <p>Vasculitis</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Cholestatic jaundice</p>
          </list-item>
          <list-item>
            <p>Elevated serum alkaline phosphatase</p>
          </list-item>
          <list-item>
            <p>Hepatitis</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
        </list>
        <p>High-dose penicillins can cause seizures, which is particularly concerning for patients with poor renal function.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Probenecid (Risk D):</bold>&#x000a0;Concurrent use of probenecid and amoxicillin-clavulanate results in&#x000a0;prolonged and&#x000a0;elevated blood concentrations of amoxicillin. Therefore, coadministration of probenecid is not recommended.</p>
          </list-item>
          <list-item>
            <p><bold>Oral Anticoagulants:</bold> Coadministration of&#x000a0;amoxicillin and oral anticoagulants may lead to&#x000a0;abnormally prolonged prothrombin time. Appropriate monitoring and dose adjustment of&#x000a0;oral anticoagulants are recommended to achieve the&#x000a0;desired level of anticoagulation.</p>
          </list-item>
          <list-item>
            <p><bold>Allopurinol:</bold> Coadministration may increase the incidence of allergic or hypersensitivity reactions associated with amoxicillin administration.</p>
          </list-item>
          <list-item>
            <p><bold>Combined Oral Contraceptives:</bold> Amoxicillin-clavulanate administration may&#x000a0;hinder the intestinal flora&#x000a0;involved&#x000a0;in estrogen reabsorption, reducing the efficacy of oral estrogen/progesterone&#x000a0;combination contraceptives.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17475.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p><bold>Liver Disease</bold>&#x000a0;</p>
        <p>There are no guidelines for dosage adjustments for patients with hepatic impairment, but extreme caution is necessary for this population. This medication is contraindicated for any patient with a prior history of amoxicillin or clavulanic acid-induced hepatic dysfunction.<xref ref-type="bibr" rid="article-17475.r42">[42]</xref></p>
        <p><bold>Hypersensitivity Reactions</bold>&#x000a0;</p>
        <p>The&#x000a0;administration of amoxicillin to patients with&#x000a0;a history of hypersensitivity reactions to amoxicillin, clavulanic acid, or other &#x003b2;-lactam antimicrobials is contraindicated. As amoxicillin is a penicillin derivative, there is a high likelihood of crossover hypersensitivity in patients with a documented penicillin allergy. In this population, clinicians should consider alternative antibiotics.<xref ref-type="bibr" rid="article-17475.r41">[41]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Renal impairment:</bold> Caution is warranted when treating patients on hemodialysis or with severe renal impairment (CrCL &#x0003c;30 mL/min). As this antibiotic is primarily eliminated renally, individuals with&#x000a0;kidney disease&#x000a0;require dose adjustments and closer monitoring.<xref ref-type="bibr" rid="article-17475.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Drug-induced enterocolitis syndrome (DIES):</bold> The FDA recently&#x000a0;listed drug-induced enterocolitis syndrome (DIES) as a potential complication of amoxicillin-clavulanate administration. Drug-induced enterocolitis syndrome (DIES) is a non-IgE-mediated hypersensitivity reaction involving the gastrointestinal system that typically occurs 2 to 4 hours after taking certain drugs. Amoxicillin&#x000a0;and&#x000a0;amoxicillin-clavulanate are frequently implicated. Symptoms include vomiting, abdominal pain, diarrhea, pallor, and dehydration, which can be severe and lead to hypovolemic shock. Neutrophilic leukocytosis is common. DIES primarily affects pediatric patients. If DIES is suspected, the offending drug should be&#x000a0;discontinued, and&#x000a0;appropriate&#x000a0;treatment should be initiated immediately.<xref ref-type="bibr" rid="article-17475.r44">[44]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Phenylketonuria:</bold>&#x000a0;Administering&#x000a0;aspartame-containing formulations of amoxicillin-clavulanic acid should be avoided for patients with this genetic disorder. Aspartame is metabolized into various components in the gastrointestinal tract, including phenylalanine. Excessive aspartame can cause&#x000a0;elevated phenylalanine levels in patients with PKU. Aspartame-free formulations should be prioritized to prevent potential neurological complications associated with elevated phenylalanine levels.<xref ref-type="bibr" rid="article-17475.r45">[45]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17475.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients taking amoxicillin-clavulanate require close monitoring for hypersensitivity and secondary infections, such as&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;colitis or candidiasis. Intermittent hepatic, renal, and hematologic function testing is indicated for prolonged treatment exceeding&#x000a0; 10 days.<xref ref-type="bibr" rid="article-17475.r42">[42]</xref>&#x000a0;Clinicians should regularly obtain liver function markers in patients with hepatic impairment up to several weeks after discontinuing amoxicillin-clavulanate.<xref ref-type="bibr" rid="article-17475.r43">[43]</xref></p>
      </sec>
      <sec id="article-17475.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p><bold>Nephrotoxicity</bold>&#x000a0;</p>
        <p>Excessive&#x000a0;amoxicillin and clavulanate potassium doses may&#x000a0;cause&#x000a0;interstitial nephritis and oliguric renal failure. Crystalluria, which can progress to renal failure, has also been reported. Higher doses of intravenous amoxicillin (HDIVA) can lead to acute kidney injury.<xref ref-type="bibr" rid="article-17475.r46">[46]</xref>&#x000a0;Immediate discontinuation of amoxicillin-clavulanate is crucial for suspected overdoses. Symptomatic treatment and supportive care should be provided as necessary. Maintaining adequate fluid intake and promoting diuresis are essential to reduce the risk of crystalluria. Hemodialysis may be considered to enhance clearance, particularly in patients with severe overdose or renal impairment.</p>
        <p>
<bold>Hepatotoxicity&#x000a0;</bold>
</p>
        <p>Amoxicillin-clavulanate is an excellent antimicrobial but is one of the most frequent causes of idiosyncratic drug-induced hepatic injury.<xref ref-type="bibr" rid="article-17475.r47">[47]</xref>&#x000a0;Men and patients older than 50 are at increased risk compared to women. Other&#x000a0;potential contributors to liver disease include&#x000a0;genetic polymorphisms, antiretroviral therapy, and concomitant use of medications that&#x000a0;affect the cytochrome P450 pathway. Symptoms generally begin 2 to 3 weeks after initiation but may occur sooner or be delayed up to 12 weeks. Treatment involves immediate discontinuation of the offending agent and limiting the use of other hepatotoxic drugs. N-acetylcysteine and corticosteroids can also considered. However, the benefits of these medications are likely marginal. Administration of a bile acid sequestrant, such as cholestyramine, may provide symptomatic relief from pruritis. The majority of patients achieve a full, albeit prolonged, recovery. Additionally, a few&#x000a0;may&#x000a0;develop liver failure and require a transplant to survive.<xref ref-type="bibr" rid="article-17475.r42">[42]</xref><xref ref-type="bibr" rid="article-17475.r43">[43]</xref><xref ref-type="bibr" rid="article-17475.r48">[48]</xref><xref ref-type="bibr" rid="article-17475.r49">[49]</xref></p>
      </sec>
      <sec id="article-17475.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All drug-related reactions, including drug-induced hepatic injury, have the potential to lead to significant morbidity or mortality if not appropriately identified and managed. Open and effective interprofessional communication is essential among all medical team members. Proper management begins in the primary care office or emergency department, with physicians maintaining broad differentials and a high index of suspicion through clinical gestalt and information gained from a thorough history and appropriate physical exam and subsequent&#x000a0;laboratory&#x000a0;testing. Patients with&#x000a0;drug-induced hepatic injury secondary to antimicrobial use&#x000a0;may&#x000a0;present with liver injury days to weeks after completing a course of antibiotics, and a direct correlation may not be straightforward. If there is suspicion of drug-induced hepatic injury, identifying and discontinuing the offending agent is the primary goal of treatment.&#x000a0;The involvement of a specialist, such as a hepatologist, can be beneficial, especially when there is a concern for acute liver failure or chronic liver disease or the diagnosis remains unclear after the initial evaluation. Furthermore, early transport to liver transplant facilities can be advantageous in patients with evidence of liver failure or who are at high risk.<xref ref-type="bibr" rid="article-17475.r50">[50]</xref>&#x000a0;Other treatment modalities include corticosteroids and N-acetylcysteine. However, the benefits are likely marginal, and their use should be in conjunction with a specialist.<xref ref-type="bibr" rid="article-17475.r49">[49]</xref></p>
        <p>In summary, proactive instead of reactive methods are always more effective. Proper antimicrobial stewardship can decrease unnecessary use of antimicrobials, reduce the incidence of drug-related adverse effects, and limit the rate of antimicrobial resistance. This stewardship is&#x000a0;only one aspect of amoxicillin-clavulanate management by an interprofessional team. Information sharing between emergency medicine and primary care physicians can help identify suspected adverse reactions early and improve appropriate antimicrobial selection for individuals undergoing treatment. The pharmacist can check dose and duration, provide antibiogram data, and&#x000a0;assess for drug interactions that may interfere with therapy. Nurses can administer the medication, counsel the patient on proper administration, and monitor for adverse events and therapeutic effectiveness. When a severe adverse reaction has occurred, the early involvement of a specialist can limit the severity of the disease and increase the chance of a complete and uneventful recovery. All these exemplify an interprofessional team approach that improves the odds of optimal patient outcomes. An interprofessional team approach and communication among clinicians (MDs, DOs, NPs, PAs), infectious disease specialists, pharmacists, and nurses are crucial to reducing adverse effects and antimicrobial resistance and enhancing patient outcomes&#x000a0;associated&#x000a0;with amoxicillin-clavulanate therapy.</p>
      </sec>
      <sec id="article-17475.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17475&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17475">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17475/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17475">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17475.s11">
        <title>References</title>
        <ref id="article-17475.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Carmine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heel</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Morley</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Speight</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Amoxycillin/clavulanic acid: a review of its antibacterial activity, pharmacokinetics and therapeutic use.</article-title>
            <source>Drugs</source>
            <year>1981</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>337</fpage>
            <page-range>337-62</page-range>
            <pub-id pub-id-type="pmid">7037354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benninger</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>10</issue>
            <fpage>1839</fpage>
            <page-range>1839-46</page-range>
            <pub-id pub-id-type="pmid">14521493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metlay</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Waterer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Anzueto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crothers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cooley</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Flanders</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Metersky</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Musher</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Restrepo</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Whitney</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2019</year>
            <month>Oct</month>
            <day>01</day>
            <volume>200</volume>
            <issue>7</issue>
            <fpage>e45</fpage>
            <page-range>e45-e67</page-range>
            <pub-id pub-id-type="pmid">31573350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pimentel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SSC</given-names>
              </name>
            </person-group>
            <article-title>ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>165</fpage>
            <page-range>165-178</page-range>
            <pub-id pub-id-type="pmid">32023228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chow</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Benninger</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Pankey</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Seleznick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Volturo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wald</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>File</surname>
                <given-names>TM</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults.</article-title>
            <source>Clin Infect Dis</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>8</issue>
            <fpage>e72</fpage>
            <page-range>e72-e112</page-range>
            <pub-id pub-id-type="pmid">22438350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Piccirillo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Chandrasekhar</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ashok Kumar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kramper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orlandi</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Corrigan</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice guideline (update): adult sinusitis.</article-title>
            <source>Otolaryngol Head Neck Surg</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>152</volume>
            <issue>2 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-S39</page-range>
            <pub-id pub-id-type="pmid">25832968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shulman</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Bisno</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Clegg</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Van Beneden</surname>
                <given-names>C</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2012</year>
            <month>Nov</month>
            <day>15</day>
            <volume>55</volume>
            <issue>10</issue>
            <fpage>e86</fpage>
            <page-range>e86-102</page-range>
            <pub-id pub-id-type="pmid">22965026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehmood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>A Rare Case of Salmonella Gastroenteritis Presenting as Aspiration Pneumonia With Pleural Empyema in an Immunocompetent Patient.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>e37192</fpage>
            <pub-id pub-id-type="pmid">37168190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Poupard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pypstra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Woodnutt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wynne</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>53 Suppl 1</volume>
            <fpage>i3</fpage>
            <page-range>i3-20</page-range>
            <pub-id pub-id-type="pmid">14726431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobs</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>353</fpage>
            <page-range>353-60</page-range>
            <pub-id pub-id-type="pmid">15954852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bucher</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Tschudi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;riat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Welge-L&#x000fc;ussen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Z&#x000fc;st</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schindler</surname>
                <given-names>C</given-names>
              </name>
              <collab>BASINUS (Basel Sinusitis Study) Invetigators</collab>
            </person-group>
            <article-title>Effect of amoxicillin-clavulanate in clinically diagnosed acute rhinosinusitis: a placebo-controlled, double-blind, randomized trial in general practice.</article-title>
            <source>Arch Intern Med</source>
            <year>2003</year>
            <month>Aug</month>
            <day>11-25</day>
            <volume>163</volume>
            <issue>15</issue>
            <fpage>1793</fpage>
            <page-range>1793-8</page-range>
            <pub-id pub-id-type="pmid">12912714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carlotta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nitin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bhaskar Kumar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Gram negative bacteria related urinary tract infections: spectrum of antimicrobial resistance over 9&#x02009;years in a University tertiary referral Hospital.</article-title>
            <source>Ther Adv Infect Dis</source>
            <year>2024</year>
            <season>Jan-Dec</season>
            <volume>11</volume>
            <fpage>20499361241228342</fpage>
            <pub-id pub-id-type="pmid">38312849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieberthal</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Chonmaitree</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ganiats</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Hoberman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Joffe</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Sevilla</surname>
                <given-names>XD</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Tunkel</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and management of acute otitis media.</article-title>
            <source>Pediatrics</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>131</volume>
            <issue>3</issue>
            <fpage>e964</fpage>
            <page-range>e964-99</page-range>
            <pub-id pub-id-type="pmid">23439909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alizai</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Haseeb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamayun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Roghani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ullah</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ijaz</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Community-Acquired Skin and Soft Tissue Infections: Epidemiology and Management in Patients Presenting to the Emergency Department of a Tertiary Care Hospital.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>e34379</fpage>
            <pub-id pub-id-type="pmid">36874676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrahamian</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Dog Bites: Bacteriology, Management, and Prevention.</article-title>
            <source>Curr Infect Dis Rep</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>446</fpage>
            <page-range>446-453</page-range>
            <pub-id pub-id-type="pmid">11095891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartman-Adams</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Banvard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Juckett</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Impetigo: diagnosis and treatment.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>Aug</month>
            <day>15</day>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>229</fpage>
            <page-range>229-35</page-range>
            <pub-id pub-id-type="pmid">25250996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Llor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moragas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bayona</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miravitlles</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2012</year>
            <month>Oct</month>
            <day>15</day>
            <volume>186</volume>
            <issue>8</issue>
            <fpage>716</fpage>
            <page-range>716-23</page-range>
            <pub-id pub-id-type="pmid">22923662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gariani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lebowitz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kressmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>von Dach</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sendi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Waibel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Berli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>U&#x000e7;kay</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Oral amoxicillin-clavulanate for treating diabetic foot infections.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>1483</fpage>
            <page-range>1483-1486</page-range>
            <pub-id pub-id-type="pmid">30719838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diniz Freitas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez Fern&#x000e1;ndez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vasallo Vidal</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Limeres Posse</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Diz Dios</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez Feijoo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Oral amoxicillin/clavulanate for the prevention of bacteremia following dental extractions.</article-title>
            <source>Oral Dis</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>2272</fpage>
            <page-range>2272-2276</page-range>
            <pub-id pub-id-type="pmid">35467064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khattri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumbargere Nagraj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eachempati</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kusum</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Bhat</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Lodi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Adjunctive systemic antimicrobials for the non-surgical treatment of periodontitis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Nov</month>
            <day>16</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD012568</fpage>
            <pub-id pub-id-type="pmid">33197289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>PY</given-names>
              </name>
            </person-group>
            <article-title>Deep neck infections in children.</article-title>
            <source>J Microbiol Immunol Infect</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>627</fpage>
            <page-range>627-633</page-range>
            <pub-id pub-id-type="pmid">26507671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsubayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Asai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A Case of Thoracic Empyema Caused by Actinomyces naeslundii.</article-title>
            <source>Am J Case Rep</source>
            <year>2024</year>
            <month>Feb</month>
            <day>18</day>
            <volume>25</volume>
            <fpage>e943030</fpage>
            <pub-id pub-id-type="pmid">38368503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title><italic>Pasteurella multocida</italic> bacteraemia with liver abscess.</article-title>
            <source>BMJ Case Rep</source>
            <year>2024</year>
            <month>Jan</month>
            <day>16</day>
            <volume>17</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">38232998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kennedy</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bulitta</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Chatham-Stephens</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Person</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mongkolrattanothai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Negron</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Postexposure Prophylaxis and Treatment of Bacillus anthracis Infections: A Systematic Review and Meta-analyses of Animal Models, 1947-2019.</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Oct</month>
            <day>17</day>
            <volume>75</volume>
            <issue>Suppl 3</issue>
            <fpage>S379</fpage>
            <page-range>S379-S391</page-range>
            <pub-id pub-id-type="pmid">36251546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sittner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ben-Shmuel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Glinert</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bar-David</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schlomovitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kobiler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Using old antibiotics to treat ancient bacterium-&#x003b2;-lactams for Bacillus anthracis meningitis.</article-title>
            <source>PLoS One</source>
            <year>2020</year>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>e0228917</fpage>
            <pub-id pub-id-type="pmid">32053632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Gurwith</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination.</article-title>
            <source>Clin Pharm</source>
            <year>1984</year>
            <season>Nov-Dec</season>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>591</fpage>
            <page-range>591-9</page-range>
            <pub-id pub-id-type="pmid">6391783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wise</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bedford</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1978</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>389</fpage>
            <page-range>389-93</page-range>
            <pub-id pub-id-type="pmid">122520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veeraraghavan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bakthavatchalam</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Sahni</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy.</article-title>
            <source>Infect Dis Ther</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-25</page-range>
            <pub-id pub-id-type="pmid">33306184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szultka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krzeminski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jackowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buszewski</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Identification of In Vitro Metabolites of Amoxicillin in Human Liver Microsomes by LC-ESI/MS.</article-title>
            <source>Chromatographia</source>
            <year>2014</year>
            <volume>77</volume>
            <issue>15</issue>
            <fpage>1027</fpage>
            <page-range>1027-1035</page-range>
            <pub-id pub-id-type="pmid">25089048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ladumor</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Unadkat</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Prediction of Pregnancy-Induced Changes in Secretory and Total Renal Clearance of Drugs Transported by Organic Anion Transporters.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>49</volume>
            <issue>10</issue>
            <fpage>929</fpage>
            <page-range>929-937</page-range>
            <pub-id pub-id-type="pmid">34315779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bax</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Development of a twice daily dosing regimen of amoxicillin/clavulanate.</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>30 Suppl 2</volume>
            <fpage>S118</fpage>
            <page-range>S118-21</page-range>
            <pub-id pub-id-type="pmid">17983732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bj&#x000f6;rnsson</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity by Drugs: The Most Common Implicated Agents.</article-title>
            <source>Int J Mol Sci</source>
            <year>2016</year>
            <month>Feb</month>
            <day>06</day>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>224</fpage>
            <pub-id pub-id-type="pmid">26861310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evans</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Purohit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colbert</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lear</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Makin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Scobie</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Sells</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Amoxycillin-clavulanic acid (Augmentin) antibiotic prophylaxis against wound infections in renal failure patients.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>1988</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>363</fpage>
            <page-range>363-9</page-range>
            <pub-id pub-id-type="pmid">3053562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <chapter-title>Amoxicillin and Clavulanic Acid</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29999835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soraci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cherubini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paoletti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Filippelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Luciani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lagan&#x000e0;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gambuzza</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Filicetti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Corsonello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lattanzio</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Safety and Tolerability of Antimicrobial Agents in the Older Patient.</article-title>
            <source>Drugs Aging</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>499</fpage>
            <page-range>499-526</page-range>
            <pub-id pub-id-type="pmid">36976501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022.</article-title>
            <source>BMC Pharmacol Toxicol</source>
            <year>2023</year>
            <month>Dec</month>
            <day>04</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <pub-id pub-id-type="pmid">38049920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iravani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Treatment of urinary tract infections with a combination of amoxicillin and clavulanic acid.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1982</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>672</fpage>
            <page-range>672-7</page-range>
            <pub-id pub-id-type="pmid">7181477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulroy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Amoxycillin rash in infectious mononucleosis.</article-title>
            <source>Br Med J</source>
            <year>1973</year>
            <month>Mar</month>
            <day>03</day>
            <volume>1</volume>
            <issue>5852</issue>
            <fpage>554</fpage>
            <pub-id pub-id-type="pmid">4266345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic-Induced Rash in Patients With Infectious Mononucleosis.</article-title>
            <source>Ann Pharmacother</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>154</fpage>
            <page-range>154-162</page-range>
            <pub-id pub-id-type="pmid">27620494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d3;nodi-Nagy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kiny&#x000f3;</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Meszes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garaczi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kem&#x000e9;ny</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bata-Cs&#x000f6;rg&#x00151;</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Amoxicillin rash in patients with infectious mononucleosis: evidence of true drug sensitization.</article-title>
            <source>Allergy Asthma Clin Immunol</source>
            <year>2015</year>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">25784943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thong</surname>
                <given-names>BY</given-names>
              </name>
            </person-group>
            <article-title>Update on the management of antibiotic allergy.</article-title>
            <source>Allergy Asthma Immunol Res</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>77</fpage>
            <page-range>77-86</page-range>
            <pub-id pub-id-type="pmid">20358021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>deLemos</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ghabril</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rockey</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barnhart</surname>
                <given-names>HX</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
              <collab>Drug-Induced Liver Injury Network (DILIN)</collab>
            </person-group>
            <article-title>Amoxicillin-Clavulanate-Induced Liver Injury.</article-title>
            <source>Dig Dis Sci</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>2406</fpage>
            <page-range>2406-2416</page-range>
            <pub-id pub-id-type="pmid">27003146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chalasani</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <collab>Practice Parameters Committee of the American College of Gastroenterology</collab>
            </person-group>
            <article-title>ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>109</volume>
            <issue>7</issue>
            <fpage>950</fpage>
            <page-range>950-66; quiz 967</page-range>
            <pub-id pub-id-type="pmid">24935270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Filippo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Venanzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ciarelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Panetti</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Di Pillo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chiarelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Attanasi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Enterocolitis Syndrome in Children.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Apr</month>
            <day>26</day>
            <volume>24</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">37175584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maler</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goetz</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tardieu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Alili</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Meunier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maillot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Labarthe</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Aspartame and Phenylketonuria: an analysis of the daily phenylalanine intake of aspartame-containing drugs marketed in France.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2023</year>
            <month>Jun</month>
            <day>08</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>142</fpage>
            <pub-id pub-id-type="pmid">37291632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demotier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Limelette</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Charmillon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baux</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Parent</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Mestrallet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pavel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Servettaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dram&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muggeo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wynckel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gozalo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taam</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fillion</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaussaud</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Trenque</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Piroth</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bani-Sadr</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hentzien</surname>
                <given-names>M</given-names>
              </name>
              <collab>CRISTAMOX Study group</collab>
            </person-group>
            <article-title>Incidence, associated factors, and effect on renal function of amoxicillin crystalluria in patients receiving high doses of intravenous amoxicillin (The CRISTAMOX Study): A cohort study.</article-title>
            <source>EClinicalMedicine</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>45</volume>
            <fpage>101340</fpage>
            <pub-id pub-id-type="pmid">35295665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rnsson</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment.</article-title>
            <source>Semin Liver Dis</source>
            <year>2024</year>
            <month>May</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>239</fpage>
            <page-range>239-257</page-range>
            <pub-id pub-id-type="pmid">38740371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hussaini</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Farrington</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Idiosyncratic drug-induced liver injury: an overview.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>673</fpage>
            <page-range>673-84</page-range>
            <pub-id pub-id-type="pmid">17967156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giordano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rivas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zervos</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>An Update on Treatment of Drug-Induced Liver Injury.</article-title>
            <source>J Clin Transl Hepatol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>74</fpage>
            <page-range>74-9</page-range>
            <pub-id pub-id-type="pmid">26356645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17475.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WM</given-names>
              </name>
              <collab>American Association for the Study of Liver Disease</collab>
            </person-group>
            <article-title>AASLD position paper: the management of acute liver failure.</article-title>
            <source>Hepatology</source>
            <year>2005</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>1179</fpage>
            <page-range>1179-97</page-range>
            <pub-id pub-id-type="pmid">15841455</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
